Dare Bioscience, Inc. Common Stock
Here’s whether Dare Bioscience, Inc. Common Stock (DARE) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.69% over 10 days); 3-month momentum positive (+52.9%); rising volume confirms the move (2.59x 30d avg). Concerns: RSI 85 — overbought, elevated pullback risk. Currently 67.9% off its 52-week high. Score: +5/7.
DARE is in a confirmed uptrend, trading above both its 50-day ($1.68) and 200-day ($1.99) moving averages. With an RSI of 84.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +1.4% compares to +35.1% for SPY (trailed the market by 33.7%). The current 67.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.